Astra Zeneca launches Imjudo in China after combination therapy wins first-line HCC approval
AstraZeneca announced the official launch in China of Imjudo® (Chinese generic name: tremelimumab). In April this year, based on positive results from the global Phase III HIMALAYA study and a Chinese cohort, the combination of tremelimumab and Imfinzi® (Chinese generic name: durvalumab) was approved in China as a first-line treatment for adults with advanced or unresectable hepatocellular carcinoma (HCC). The report was published by Jiemian.
AstraZeneca announced the official launch in China of Imjudo® (Chinese generic name: tremelimumab).
In April this year, based on positive results from the global Phase III HIMALAYA study and a Chinese cohort, the combination of tremelimumab and Imfinzi® (Chinese generic name: durvalumab) was approved in China as a first-line treatment for adults with advanced or unresectable hepatocellular carcinoma (HCC).
The report was published by Jiemian.
In April this year, based on positive results from the global Phase III HIMALAYA study and a Chinese cohort, the combination of tremelimumab and Imfinzi® (Chinese generic name: durvalumab) was approved in China as a first-line treatment for adults with advanced or unresectable hepatocellular carcinoma (HCC).
The report was published by Jiemian.